NCT05618041
The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies
Recruiting · Not Applicable · Hebei Senlang Biotechnology Inc., Ltd. · registry updated 2025-06-24
Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.
To evaluate the tolerability and safety of CAR-T technology in patients with relapsed or refractory hematolymphoid malignancies.
Inclusion
- Sign the informed consent and be willing and able to comply with the visit, treatment protocol, laboratory examination, and other requirements of the study as specified in the study procedure sheet;
- Diagnosed as recurrent or refractory lymphoma, leukemia or myeloma;
- Tumor cells express targets for CAR-T cell therapy (results: flow cytometry or Immunohistochemical test confirmation);
- Age 14-75 (including threshold), gender unlimited;
- Eastern Cooperative Oncology Group (ECOG) score ≤2;
- HGB ≥ 70g/L (blood transfusion allowed);
Exclusion
- Severe cardiac insufficiency;
- Have a history of severe lung impairment;
- Complicated with other advanced malignant tumors;
- Complicated with severe or persistent infection that cannot be effectively controlled;
- Complicated with severe autoimmune diseases or congenital immune deficiency;
- Active hepatitis (HBV DNA or HCV RNA positive);